Sorry!! The article you are trying to read is not available now.
Thank you very much;
you're only a step away from
downloading your reports.

Testosterone Gel Maker BioSante Shares Soar on Drug Approval


But the rise seems unwarranted given the company's "female Viagra" setback in December. Can BioSante and Teva compete for treatment of men with low testosterone?

The government approved a product developed by BioSante Pharmaceuticals (BPAX) and the company's shares jumped almost 50%. Great news for this beaten-up stock? Actually, it's an overreaction to a moderately positive event.

BioSante just won US approval for a product analysts say has little upside potential -- not to mention one that's licensed out to partner Teva Pharmaceutical Industries (TEVA). The approval of the product, Bio-T-Gel, is not the long-term answer for BioSante.

BioSante still hasn't fully recovered from the debacle of LibiGel, a drug billed as a libido-enhancing testosterone gel for women with low sex drives. The company spent more than a decade studying the drug, losing more than $200 million in the process, only to see the treatment fail in a late-stage study in December. (See Female Viagra Drug Failure Causes BioSante Shares to Plunge 77%)

The company is still trying to determine "the best path forward for LibiGel," CEO Stephen Simes told investors at a New York conference Tuesday.

But Simes seems to already be moving on from LibiGel as he spent a good chunk of Tuesday's presentation talking about the company's early-stage cancer drugs. There are 17 early phase studies being conducted on cancer vaccines, which aim to use patients' immune systems to fight off the disease, he says.

BioSante has the "widest portfolio of cancer vaccines in development," Simes boasts.

These studies are far too early for anyone to buy on the hope for promising new cancer drugs. And, frankly, the company has some work to do rebuilding its reputation.

But clearly the just-approved Bio-T Gel is not going to save BioSante. Like LibiGel, the product is a testosterone treatment. But Bio-T-Gel is a product designed for men who have low testosterone levels. The product is aimed at treating a condition known as hypogonadism, which can result in low sex drive, impotence, muscle weakness and osteoporosis, according to BioSante.

The condition actually represents a big market opportunity, but as Rodman & Renshaw analyst Elemer Piros notes, Teva and BioSante are late to the party.

Piros says the market for men with low testosterone probably is a more than $1 billion sales opportunity but several other companies already have products on the market. Abbott Laboratories (ABT) won US approval for a product called AndroGel last year. In fact, Abbott sued Teva saying Bio-T-Gel infringed on Abbott's patent. The suit was settled in December and terms weren't disclosed.

"While the market is sizable," Piros says. "Teva will be the fifth entrant, therefore we don't assume significant royalties to BioSante."

Simes says the royalties on the product are between 5% and 10%. Piros estimates that figure is more like 5% to 7.5%.

"As the company recovers from the LibiGel (study) setback, we believe the company's current and future pipeline may drive shareholder value," Piros says. He has a hold rating on the stock.

After surging almost 50% early Wednesday, the shares were still up 38% to $1.05 in midday trading. Since going public in 2000, the company's shares have lost 88%.

Twitter: @brettchase

Follow the markets all day every day with a FREE 14 day trial to Buzz & Banter. Over 30 professional traders share their ideas in real-time. Learn more.
< Previous
  • 1
Next >
No positions in stocks mentioned.
The information on this website solely reflects the analysis of or opinion about the performance of securities and financial markets by the writers whose articles appear on the site. The views expressed by the writers are not necessarily the views of Minyanville Media, Inc. or members of its management. Nothing contained on the website is intended to constitute a recommendation or advice addressed to an individual investor or category of investors to purchase, sell or hold any security, or to take any action with respect to the prospective movement of the securities markets or to solicit the purchase or sale of any security. Any investment decisions must be made by the reader either individually or in consultation with his or her investment professional. Minyanville writers and staff may trade or hold positions in securities that are discussed in articles appearing on the website. Writers of articles are required to disclose whether they have a position in any stock or fund discussed in an article, but are not permitted to disclose the size or direction of the position. Nothing on this website is intended to solicit business of any kind for a writer's business or fund. Minyanville management and staff as well as contributing writers will not respond to emails or other communications requesting investment advice.

Copyright 2011 Minyanville Media, Inc. All Rights Reserved.
Featured Videos